Skip to main content

Table 3 The results of subgroup analysis

From: Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy

Outcomes

CCRT HR(95% CI)

P value

CCRT + AC HR(95% CI)

P value

OS

1.04 (0.74–1.47)

0.82

0.78 (0.32–1.86)

0.57

DFS

0.96 (0.48–1.92)

0.92

0.81 (0.33–1.99)

0.65

  1. DFS: disease-free survival; OS: overall survival;CCRT: concurrent chemoradiotherapy; AC:adjuvant
  2. chemotherapy;HR: hazard ratio;CI:confifidence interval
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us